Targeting cancer with power and precision


Sesen Bio, Inc. (NASDAQ: SESN), previously Eleven Biotherapeutics, Inc., is a late-stage company developing next-generation antibody-drug conjugate (ADC) therapies for patients with cancer. Their approach aims to overcome limitations of traditional ADCs by incorporating a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively, effectively and broadly kill cancer cells while sparing healthy cells. These single protein molecules are known as fusion proteins. Their lead program, Vicinium™, is a novel fusion protein currently in Phase 3 development for the treatment of patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin (BCG).


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.sesenbio.com

Recent News

April 12, 2018
New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting

April 4, 2018
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress

April 3, 2018
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner

Abbie Celniker, Ph.D.
Partner